북미 간질성 방광염 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

북미 간질성 방광염 시장 – 2029년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Oct 2022
  • North America
  • 350 Pages
  • 테이블 수: 220
  • 그림 수: 60

>북미 간질성 방광염 시장, 심각도(경미한 것에서 중간 정도, 중간에서 심각한 것), 치료 유형(약물, 방광 주입, 보툴리눔 독소 A, 신경 자극 및 수술 ), 투여 경로(경구, 비경구, 방광 내, 국소 및 기타), 구매 방식( 처방전 없이 구입 가능한 약과 처방약), 환자 유형(소아 및 성인), 최종 사용자(병원, 진료소, 가정 의료 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타) - 업계 동향 및 2029년까지의 예측.

북미 간질성 방광염 시장

북미 간질성 방광염 시장 분석 및 규모

간질성 방광염(IC)이라고 하는 방광 통증 상태의 한 형태는 원인을 알 수 없는 방광과 골반저에 지속적인 통증을 유발합니다. 여성 비뇨기과적 지속적 골반 불편 증후군이라고 합니다. 즉시 자주 소변을 보아야 한다는 느낌이 증상입니다. 삶의 질 저하와 우울증은 IC/BPS와 관련이 있습니다. 영향을 받는 사람들 중 다수는 섬유근육통과 과민성 대장 증후군을 겪기도 합니다.

간질성 방광염 시장

간질성 방광염 시장

북미 간질성 방광염 시장은 2022년부터 2029년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년부터 2029년까지의 예측 기간 동안 10.8%의 CAGR로 성장하고 있으며 2029년까지 1,123.31백만 달러에 도달할 것으로 분석합니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020 (2019-2014로 사용자 정의 가능)

양적 단위

수익 (단위: USD 백만)

다루는 세그먼트

심각도(경미~중간 및 중간~중증), 치료 유형(약물, 방광 주입, 보툴리눔 독소 A, 신경 자극수술 ), 투여 경로(경구, 비경구, 방광 내, 국소 및 기타), 구매 방식( 처방전 없이 구입 가능한 약물 및 처방약), 환자 유형(소아 및 성인), 최종 사용자(병원, 진료소, 가정 의료 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타)

적용 국가

미국, 캐나다, 멕시코.

시장 참여자 포함

Alvogen, Janssen Pharmaceuticals, Inc., Sandoz AG, Sun Pharmaceutical Industries Ltd., Accord Healthcare US, Avet Pharmaceuticals Inc., Lannett, Viatris Inc., Pfizer, Inc., Strides Pharma Science Limited, GSK plc. Prestige Consumer Healthcare Inc., Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals, Inc., Apotex Inc., Aurobindo Pharma USA, VistaPharm, Inc., Dr. Reddy's Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Bayer AG, Reckitt Benckiser Group PLC 등이 있습니다.

시장 정의

A persistent illness known as interstitial cystitis causes bladder pressure, bladder pain and pelvic pain. Mild discomfort to severe agony is all possible levels of pain. The disorder belongs to a group of illnesses called painful bladder syndrome. Different tests are performed by doctors to diagnose the painful bladder disorder, which include X-rays, urine tests and a bladder wall examination using a cystoscope. It is characterized by pain, pressure, or discomfort perceived to be related to the urinary bladder that lasts more than six months with at least one other urinary symptom, such as frequency or persistent urge. These bladder disorders cause inflammation in the bladder, which is generally called cystitis. Treatment of the disorder depends on the cause of the problem. It may include medication and surgery in severe cases.

Interstitial Cystitis Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail as below:

Drivers

  •  INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC)

The disorder known as interstitial cystitis (IC), also known as bladder discomfort syndrome, is chronic or long-lasting and it produces uncomfortable urine symptoms. Individuals with IC may experience varied symptoms. For example, some persons experience little pressure, pain, or discomfort in the pelvic region. Others may battle with severe bladder pain, urinary urgency—the sudden need to urinate—or frequency—the desire to urinate more frequently. One of the main factors influencing the growth rate of the interstitial cystitis market is the increasing prevalence of interstitial cystitis nowadays. Women are particularly affected by this condition. Common side effects include allergies, fibromyalgia and endometriosis. Urinary frequency, urgency and pelvic pain are clinical symptoms of interstitial cystitis, which can occur both during the day and at night.

  • RISE IN HEALTHCARE EXPENDITURE

The cost of healthcare has climbed globally as people's disposable income has increased in different countries. Additionally, government agencies and healthcare providers are taking the initiative by increasing healthcare spending in order to meet population needs.

For instance,

  • As per December 2020, World Health Organization (WHO) report stated that healthcare expenditure was rising in 2018, which was USD 8.3 trillion, which is around 10% of GDP (USD1.080 per citizen) compared to USD 7.6 trillion in 2016. Moreover, global health spending grew by 3.9 percent between 2000 and 2017.

Growing healthcare expenditure is also benefiting further economic growth and healthcare sector growth. It is primarily helpful as it significantly affects the development of better and advanced medical products in the market. Thereby surge in healthcare expenditure is expected to act as a driver for the interstitial cystitis market.

Opportunities

  • IMPROVING HEALTHCARE SYSTEM

 Interstitial cystitis or bladder pain syndrome is a chronic pelvic pain syndrome related to the urinary bladder. It is characterized by pain, pressure, or discomfort perceived to be related to the urinary bladder that lasts more than six months with at least one other urinary symptom, such as frequency or persistent urge. Thus, improvement in one or more symptoms of bladder pain can be particularly effective in improving residual urine and bladder hyperextension.

As a result of rising infectious diseases worldwide, it is required to build a better healthcare system for the diagnosis of various infections in underdeveloped regions. Improving healthcare systems in underdeveloped regions can fuel market growth over the forecast period.

These awareness programs helped people understand the correct treatment at an appropriate time. This increasing awareness allows the consumers to select novel treatments as per age and it is efficacy, which enhances the sales of different types of products. Thus, improving a better healthcare system is expected to act as an opportunity for North America interstitial cystitis market growth in the forecasted period.

Restraints/Challenges

However, the barriers to interstitial cystitis treatment techniques and the high cost of the treatment process in some regions may impede the growth of interstitial cystitis treatment hampering the market growth. Additionally, high competition in medical technology industries and long lead time for the overseas qualification can be challenging factors for the growth of the market.

This interstitial cystitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lung cancer surgery market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you to make an informed market decision to achieve market growth.

Recent Development

  • In July 2020, UCB and Ferring Pharmaceuticals Inc. announced they had entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA used for interstitial cystitis.
  • In April 2021, Kyorin Pharmaceutical Co., Ltd., a wholly owned subsidiary of KYORIN Holdings, Inc., launched Interstitial cystitis “Zymso Intravesical Solution 50 %.

North America Interstitial Cystitis Market Scope

북미 간질성 방광염 시장은 심각도, 치료 유형, 투여 경로, 구매 방식, 환자 유형, 최종 사용자 및 유통 채널로 세분화됩니다. 이러한 세그먼트 간의 성장은 산업의 빈약한 성장 세그먼트를 분석하고 사용자에게 핵심 시장 응용 프로그램을 식별하기 위한 전략적 결정을 내릴 수 있는 귀중한 시장 개요와 시장 통찰력을 제공하는 데 도움이 됩니다.

심각성

  • 약간 ~ 보통
  • 중간에서 심각

심각도를 기준으로 북미 간질성 방광염 시장은 경증에서 중등도, 중등도에서 중증으로 구분됩니다.

치료 유형

  • 약물
  • 방광 주입
  • 보툴리눔 독소 A
  • 신경 자극
  • 수술

치료 유형을 기준으로 북미 간질성 방광염 시장은 약물, 방광 주입, 보툴리눔 독소 A, 신경 자극 및 수술로 구분됩니다.

투여 경로

  • 경구
  • 비경구적
  • 방광내
  • 뉴스 영화
  • 기타

투여 경로를 기준으로 북미 간질성 방광염 시장은 경구, 비경구, 방광내, 국소 및 기타로 구분됩니다.

구매 방식

  • 카운터 너머
  • 처방

구매 방식을 기준으로 북미 간질성 방광염 시장은 일반 의약품과 처방 의약품으로 구분됩니다.

환자 유형

  • 소아과
  • 성인

환자 유형을 기준으로 북미 간질성 방광염 시장은 소아와 성인으로 구분됩니다.

최종 사용자

  • 병원
  • 클리닉
  • 홈 헬스케어
  • 기타

북미 간질성 방광염 시장은 최종 사용자를 기준으로 병원, 진료소, 가정 건강 관리 및 기타로 구분됩니다.

유통 채널

  • 직접 입찰
  • 소매 판매
  • 기타

간질성 방광염 시장

북미 간질성 방광염 시장은 유통 채널을 기준으로 직접 입찰, 소매 판매 및 기타로 구분됩니다.

간질성 방광염 시장 지역 분석/통찰력            

간질성 방광염 시장을 분석하고, 위에 언급된 대로 국가, 심각도, 치료 유형, 투여 경로, 구매 방식, 환자 유형, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

미국은 시장 점유율과 수익 면에서 북미 간질성 방광염 시장을 지배하고 있으며 예측 기간 동안에도 지배력을 계속 유지할 것입니다. 이는 이 지역에서 간질성 방광염 치료 프로세스의 검증 및 검증에 대한 필요성이 증가하고 있으며, 신속한 연구 개발이 시장을 촉진하고 있기 때문입니다.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규정의 변화를 제공합니다. 신규 및 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 국내 및 국내 브랜드와의 치열한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 간질성 방광염 시장 점유율 분석

간질성 방광염 시장 경쟁 구도는 경쟁자들의 세부 정보를 제공합니다. 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 포함됩니다. 위의 데이터 포인트는 간질성 방광염 시장에 대한 회사의 초점과만 관련이 있습니다.

간질성 방광염 시장에서 활동하는 주요 기업으로는 Alvogen, Janssen Pharmaceuticals, Inc., Sandoz AG, Sun Pharmaceutical Industries Ltd., Accord Healthcare US, .Avet Pharmaceuticals Inc., Lannett, Viatris Inc., Pfizer, Inc., Strides Pharma Science Limited, GSK plc. Prestige Consumer Healthcare Inc., Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals, Inc., Apotex Inc., Aurobindo Pharma USA, VistaPharm, Inc., Dr. Reddy's Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Bayer AG, Reckitt Benckiser Group PLC 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 북미 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA INTERSTITIAL CYSTITIS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES

4.3 PIPELINE ANALYSIS FOR INTERSTITIAL CYSTITIS TREATMENT MARKET

4.4 EPIDEMIOLOGY

5 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: REGULATIONS

5.1 FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES

5.2 EUROPEAN MEDICINES AGENCY (EMA) GUIDELINES

5.3 JAPAN REGULATORY GUIDANCE

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC)

6.1.2 RISE IN HEALTHCARE EXPENDITURE

6.1.3 STRATEGIC INITIATIVES OF KEY PLAYERS

6.1.4 INCREASE IN R&D EFFORTS IN THE HEALTHCARE INDUSTRY

6.1.5 RISING DISEASE MANAGEMENT PROGRAMS

6.2 RESTRAINTS

6.2.1 HIGH COST OF TREATMENT OF INTERSTITIAL CYSTITIS

6.2.2 LACK OF AWARENESS ABOUT BLADDER DISORDERS-RELATED PROBLEMS

6.2.3 DEARTH OF SKILLED PROFESSIONALS

6.3 OPPORTUNITIES

6.3.1 FAVORABLE REIMBURSEMENT SCENARIO

6.3.2 INCREASE IN DRUG APPROVALS AND LAUNCHES

6.3.3 IMPROVING HEALTHCARE SYSTEM

6.3.4 COMBINATION OF DIFFERENT TARGET THERAPIES

6.4 CHALLENGES

6.4.1 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL

6.4.2 PATENT EXPIRY OF DRUGS

7 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY

7.1 OVERVIEW

7.2 MILD TO MODERATE

7.3 MODERATE TO SEVERE

8 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE

8.1 OVERVIEW

8.2 MEDICATIONS

8.2.1 ANALGESICS

8.2.1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

8.2.1.1.1 IBUPROFEN

8.2.1.1.2 NAPROXEN

8.2.1.1.3 OTHERS

8.2.1.2 ACETAMINOPHEN

8.2.1.3 NON-NARCOTIC PAIN MEDICATION

8.2.1.3.1 METHENAMINE

8.2.1.3.2 PHENAZOPYRIDINE

8.2.1.3.3 OTHERS

8.2.1.4 NARCOTIC PAIN MEDICATION

8.2.1.4.1 CODEINE

8.2.1.4.2 HYDROCODONE

8.2.1.4.3 OXYCODONE

8.2.1.4.4 OXYMORPHONE

8.2.1.4.5 MORPHINE

8.2.1.4.6 HYDROMORPHONE

8.2.1.4.7 METHADONE

8.2.1.4.8 OTHERS

8.2.2 ANTIHISTAMINES

8.2.2.1 LORATADINE

8.2.2.2 HYDROXYZINE

8.2.2.3 OTHERS

8.2.3 TRICYCLIC ANTIDEPRESSANTS

8.2.3.1 AMITRIPTYLINE

8.2.3.2 IMIPRAMINE

8.2.3.3 OTHERS

8.2.4 IMMUNOSUPPRESSANTS

8.2.4.1 CYCLOSPORINE

8.2.4.2 MYCOPHENOLATE

8.2.4.3 OTHERS

8.2.5 PENTOSAN POLYSULFATE SODIUM

8.2.6 OTHERS

8.2.6.1 ALPHA BLOCKERS

8.2.6.1.1 DOXAZOSIN

8.2.6.1.2 TERAZOSIN

8.2.6.1.3 TAMSULOSIN

8.2.6.1.4 OTHERS

8.2.6.2 AMPHETAMINES

8.2.6.3 LEUKOTRIENE INHIBITORS

8.2.6.3.1 MONTELUKAST

8.2.6.3.2 ZAFIRLUKAST

8.2.6.3.3 OTHERS

8.2.6.4 OTHERS

8.3 BLADDER INSTILLATIONS

8.3.1 DIMETHYL SULFOXIDE

8.3.2 HEPARIN

8.3.3 OTHERS

8.4 BOTULINUM TOXIN A

8.5 SURGERY

8.5.1 FULGURATION

8.5.2 RESECTION

8.5.3 BLADDER AUGMENTATION

8.6 NERVE STIMULATIONS

9 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW

9.2 ORAL

9.2.1 TABLETS

9.2.1.1 EXTENDED RELEASE

9.2.1.2 IMMEDIATE RELEASE

9.2.2 CAPSULES

9.2.3 OTHERS

9.3 PARENTERAL

9.4 INTRAVESICAL

9.5 TOPICAL

9.6 OTHERS

10 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE

10.1 OVERVIEW

10.2 OVER THE COUNTER

10.3 PRESCRIPTION

11 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE

11.1 OVERVIEW

11.2 ADULTS

11.3 PEDIATRIC

12 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.3 CLINICS

12.4 HOME HEALTHCARE

12.5 OTHERS

13 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAIL SALES

13.3.1 PHARMACY STORES

13.3.2 ONLINE RETAIL CHANNEL

13.3.3 OTHERS

13.4 OTHERS

14 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY GEOGRAPHY

14.1 NORTH AMERICA

14.1.1 U.S.

14.1.2 CANADA

14.1.3 MEXICO

15 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 TEVA PHARMACEUTICALS INDUSTRIES LTD.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 PRODUCT PORTFOLIO

17.1.4 RECENT DEVELOPMENTS

17.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG)

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 HIKMA PHARMACEUTICALS PLC

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENTS

17.4 DR. REDDY'S LABORATORIES LTD

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 BAYER AG

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 AMNEAL PHARMACEUTICAL LLC.

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENTS

17.7 APOTEX

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT DEVELOPMENT

17.8 AUROBINDO PHARMA USA

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENT

17.9 AVET PHARMACEUTICALS INC.

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

17.1 ALVOGEN

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 10.3RECENT DEVELOPMENT

17.11 ACCORD-UK LTD

17.11.1 COMPANY SNAPSHOT

17.11.2 PRODUCT PORTFOLIO

17.11.3 11.3RECENT DEVELOPMENT

17.12 GLAXOSMITHKLINE PLC

17.12.1 COMPANY SNAPSHOT

17.12.2 12.2REVENUE ANALYSIS

17.12.3 PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENT

17.13 JOHNSON & JOHNSON SERVICES, INC.

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 LANNETT

17.14.1 COMPANY SNAPSHOT

17.14.2 REVENUE ANALYSIS

17.14.3 PRODUCT PORTFOLIO

17.14.4 RECENT DEVELOPMENT

17.15 PRESTIGE CONSUMER HEALTHCARE

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENTS

17.16 PFIZER INC.

17.16.1 COMPANY SNAPSHOT

17.16.2 REVENUE ANALYSIS

17.16.3 PRODUCT PORTFOLIO

17.16.4 RECENT DEVELOPMENT

17.17 RECKITT BENCKISER GROUP PLC.

17.17.1 COMPANY SNAPSHOT

17.17.2 REVENUE ANALYSIS

17.17.3 PRODUCT PORTFOLIO

17.17.4 RECENT DEVELOPMENT

17.18 SUN PHARMACEUTICAL INDUSTRIES LTD.

17.18.1 COMPANY SNAPSHOT

17.18.2 REVENUE ANALYSIS

17.18.3 PRODUCT PORTFOLIO

17.18.4 RECENT DEVELOPMENT

17.19 STRIDES PHARMA SCIENCE LIMITED.

17.19.1 COMPANY SNAPSHOT

17.19.2 REVENUE ANALYSIS

17.19.3 PRODUCT PORTFOLIO

17.19.4 RECENT DEVELOPMENT

17.2 VIATRIS INC.

17.20.1 COMPANY SNAPSHOT

17.20.2 REVENUE ANALYSIS

17.20.3 PRODUCT PORTFOLIO

17.20.4 RECENT DEVELOPMENT

17.21 VISTA PHARM INC.

17.21.1 COMPANY SNAPSHOT

17.21.2 PRODUCT PORTFOLIO

17.21.3 RECENT DEVELOPMENTS

17.22 ZYDUS PHARMACEUTICALS INC.,

17.22.1 COMPANY SNAPSHOT

17.22.2 REVENUE ANALYSIS

17.22.3 PRODUCT PORTFOLIO

17.22.4 RECENT DEVELOPMENTS

18 QUESTIONNAIRE

19 RELATED REPORTS

표 목록

TABLE 1 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED

TABLE 2 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA MILD TO MODERATE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA MODERATE TO SEVERE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA BOTULINUM TOXIN A IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA NERVE STIMULATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA PARENTERAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA INTRAVESICAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA TOPICAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA OVER THE COUNTER IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA PRESCRIPTION IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA ADULTS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA PEDIATRIC IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA HOSPITALS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA CLINICS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA HOME HEALTHCARE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA DIRECT TENDER IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 45 NORTH AMERICA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 46 NORTH AMERICA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 47 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 48 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 49 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)

TABLE 50 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 51 NORTH AMERICA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 NORTH AMERICA ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 NORTH AMERICA NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 NORTH AMERICA NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 NORTH AMERICA ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 NORTH AMERICA IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 58 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 NORTH AMERICA ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 NORTH AMERICA LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 NORTH AMERICA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 NORTH AMERICA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 65 NORTH AMERICA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 66 NORTH AMERICA TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 67 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 68 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 69 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 70 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 71 NORTH AMERICA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 72 U.S. INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)

TABLE 73 U.S. INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 74 U.S. MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 U.S. ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 U.S. NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 U.S. NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 U.S. ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 U.S. IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 U.S. TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 U.S. OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 83 U.S. ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 84 U.S. LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 85 U.S. BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 U.S. SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 U.S. INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 88 U.S. ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 89 U.S. TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 90 U.S. INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 91 U.S. INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 92 U.S. INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 93 U.S. INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 94 U.S. RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 95 CANADA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)

TABLE 96 CANADA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 97 CANADA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 98 CANADA ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 99 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 CANADA NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 101 CANADA NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 CANADA ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 103 CANADA IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 CANADA TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 CANADA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 106 CANADA ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 107 CANADA LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 CANADA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 109 CANADA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 110 CANADA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 111 CANADA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 112 CANADA TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 113 CANADA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 114 CANADA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 115 CANADA INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 116 CANADA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 117 CANADA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 118 MEXICO INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)

TABLE 119 MEXICO INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 120 MEXICO MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 MEXICO ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 122 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 123 MEXICO NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 124 MEXICO NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 125 MEXICO ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 126 MEXICO IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 127 MEXICO TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 MEXICO OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 129 MEXICO ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 130 MEXICO LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 131 MEXICO BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 132 MEXICO SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 133 MEXICO INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 134 MEXICO ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 135 MEXICO TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 136 MEXICO INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)

TABLE 137 MEXICO INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 138 MEXICO INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 139 MEXICO INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 140 MEXICO RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA BLADDER DISORDERS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SEGMENTATION

FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF INTERSTITIAL CYSTITIS IS EXPECTED TO DRIVE THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 MILD TO MODERATE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET

FIGURE 14 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2021

FIGURE 15 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2022-2029 (USD MILLION)

FIGURE 16 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, CAGR (2022-2029)

FIGURE 17 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, LIFELINE CURVE

FIGURE 18 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2021

FIGURE 19 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)

FIGURE 20 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)

FIGURE 21 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 22 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 23 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 24 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 25 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2021

FIGURE 27 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)

FIGURE 28 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)

FIGURE 29 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE

FIGURE 30 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2021

FIGURE 31 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)

FIGURE 32 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 33 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 34 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, 2021

FIGURE 35 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 36 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 37 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 39 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 40 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 41 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021)

FIGURE 43 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021)

FIGURE 44 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 45 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 46 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029)

FIGURE 47 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.